The Development Team at Carbon Biosciences is responsible for advancing the company's proprietary gene therapy platform. This includes designing and optimizing novel parvovirus-based vectors, conducting preclinical studies to assess efficacy and safety, and developing analytical methods to ensure product quality. The team works collaboratively to push the boundaries of gene therapy, targeting specific diseases with high unmet needs.
Gillian Payne
VP, Analytical Sciences
Jeff Moffit
VP & Head of Nonclinical Devel...
Jeff Moffit, PhD, DA...
Vice President, Head of Noncli...
Ryan Farrell
Senior Engineer
Sebastian Aguirre
VP, Platform Development
Sebastian Aguirre Ko...
Co-Founder, Vice President, He...
Yoshi Hashimoto
Director Of Novel Vector Devel...
View all